Recommendations for urine drug monitoring as a component of opioid therapy in the treatment of chronic pain

Pain Medicine (United States)

Volumn 13, Issue 7, 2012, Pages 886-896

  Peppin, John F ^a   Passik, Steven D ^b   Couto, Joseph E ^c   Fine, Perry G ^d   Christo, Paul J ^e   Argoff, Charles ^f   Aronoff, Gerald M ^g   Bennett, Daniel ^h   Cheatle, Martin D ⁱ   Slevin, Kieran A ^j   Goldfarb, Neil I ^k  

^a The Pain Treatment Center of the Bluegrass   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f ALBANY MEDICAL COLLEGE   (United States)

^g Carolina Pain Associates   (United States)

^h Integrative Treatment Centers   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j Greater Philadelphia Business Coalition on Health ^*

^k Greater Philadelphia Business Coalition on Health   (United States)

more..

Author keywords

Addiction; Chronic Pain; Drug Toxicology Screens; Opioids; Pain Management

Indexed keywords

AMPHETAMINE; BENZODIAZEPINE; CANNABIS; COCAINE; CODEINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; ILLICIT DRUG; METHADONE; MORPHINE; OPIATE; OXYCODONE; PETHIDINE; PRESCRIPTION DRUG;

ARTICLE; CHRONIC PAIN; CLINICAL PRACTICE; CONSENSUS; DRUG MONITORING; DRUG RESEARCH; DRUG URINE LEVEL; HUMAN; IMMUNOASSAY; MEDICAL LITERATURE; PRIMARY MEDICAL CARE; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME; URINE DRUG MONITORING;

EID: 84863883474     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2012.01414.x     Document Type: Review

References (51)

1. Webster LR, Dove B. Avoiding Opioid Abuse While Managing Pain: A Guide for Practitioners. North Branch, MN: Sunrise River Press; 2007.
2. Zacny J, Bigelow G, Compton P, etal. College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: Position statement. Drug Alcohol Depend 2003;69(3):215-32.
3. Caudill-Slosberg MA, Schwartz LM, Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs 2000. Pain 2004;109(3):514-9.
4. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: Concerns and strategies. Drug Alcohol Depend 2006;81(2):103-7.
5. Olsen Y, Daumit GL, Ford DE. Opioid prescriptions by U.S. primary care physicians from 1992 to 2001. J Pain 2006;7(4):225-35.
6. Kuehn BM. Opioid prescriptions soar: Increase in legitimate use as well as abuse. JAMA 2007;297(3):249-51.
7. Centers for Disease Control and Prevention (CDC). Emergency department visits involving nonmedical use of selected prescription drugs-United States, 2004-2008. MMWR Morb Mortal Wkly Rep 2010;59(23):705-9.
8. Substance Abuse and Mental Health Services Administration (SAMHSA). Drug Abuse Warning Network (DAWN). 2009. Available at: (accessed January 2011).
9. Adams NJ, Plane MB, Fleming MF, etal. Opioids and the treatment of chronic pain in a primary care sample. J Pain Symptom Manage 2001;22(3):791-6.
10. Bhamb B, Brown D, Hariharan J, etal. Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain. Curr Med Res Opin 2006;22(9):1859-65.
11. Boulanger A, Clark AJ, Squire P, Cui E, Horbay GL. Chronic pain in Canada: Have we improved our management of chronic noncancer pain? Pain Res Manag 2007;12(1):39-47.
12. Reisfield GM, Graham NA, Gold MS. Urine drug testing is still an invaluable resource for primary care. Ann Intern Med 2010;153(6):420; author reply 420-1.
13. Starrels JL, Becker WC, Alford DP, etal. Systematic review: Treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med 2010;152(11):712-20.
14. Chou R, Fanciullo GJ, Fine PG, etal. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10(2):113-30.
15. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: A rational approach to the treatment of chronic pain. Pain Med 2005;6(2):107-12.
16. Federation of State Medical Boards of the United States, Inc. Model policy for the use of controlled substances for the treatment of pain. J Pain Palliat Care Pharmacother 2005;19(2):73-8.
17. Health Regulation Committee. Statement of estimated regulatory costs for the standards of practice for physicians practicing in Pain Management Clinics Bill. 2010. (2010A Special Session):SB 1990.
18. Linstone HA, Turoff M, eds. The Delphi Method: Techniques and Applications. Reading, MA: Addison-Wesley; 1975.
19. Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med 2008;9(4):444-59.
20. Katz NP, Sherburne S, Beach M, etal. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg 2003;97(4):1097-102 (table of contents).
21. Michna E, Jamison RN, Pham LD, etal. Urine toxicology screening among chronic pain patients on opioid therapy: Frequency and predictability of abnormal findings. Clin J Pain 2007;23(2):173-9.
22. Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain 2007;8(7):573-82.
23. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011;34(suppl 1):S11-61.
24. EPR-3" with "National Heart, Lung, and Blood Institute. Expert panel report 3: Guidelines for the diagnosis and management of asthma (EPR-3 2007). 2007; NIH Publication No. 07-4051.
25. Heit HA, Gourlay DL. Urine drug testing in pain medicine. J Pain Symptom Manage 2004;27(3):260-7.
26. Christo PJ, Manchikanti L, Ruan X, etal. Urine drug testing in chronic pain. Pain Physician 2011;14(2):123-43.
27. iScreen. One step drug screen test card (urine) [package insert]. Norfolk, VA: Instant Technologies, Inc. 2006.
28. CRLstat Monitect 5 multi-drug screen panel [package insert]. Lenexa, KS: Clinical Reference Lab. 2005.
29. Fraser AD, Zamecnik J. Impact of lowering the screening and confirmation cutoff values for urine drug testing based on dilution indicators. Ther Drug Monit 2003;25(6):723-7.
30. Jaffee WB, Trucco E, Teter C, Levy S, Weiss RD. Focus on alcohol and drug abuse: Ensuring validity in urine drug testing. Psychiatr Serv 2008;59(2):140-2.
31. Gourlay DL, Heit HA. Pain and addiction: Managing risk through comprehensive care. J Addict Dis 2008;27(3):23-30.
32. Howard JC, Steinke DT, Donahue DM, etal. Exploring the economic impact of a pre-evaluation unit in a pain clinic. University of Kentucky 2008 Policy Summer Research Program. 2008.
33. Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain 2008;9(4):360-72.
34. Chapman CR, Lipschitz DL, Angst MS, etal. Opioid pharmacotherapy for chronic non-cancer pain in the United States: A research guideline for developing an evidence-base. J Pain 2010;11(9):807-29.
35. Moore TM, Jones T, Browder JH, Daffron S, Passik SD. A comparison of common screening methods for predicting aberrant drug-related behavior among patients receiving opioids for chronic pain management. Pain Med 2009;10(8):1426-33.
36. Smith HK. Identifying patients at risk for pain medication misuse. In: Smith HS, ed. Opioid Therapy in the 21st Century. New York, NY: Oxford University Press; 2008:101-6.
37. Webster LR, Fine PG. Approaches to improve pain relief while minimizing opioid abuse liability. J Pain 2010;11(7):602-11.
38. Ekholm O, Gronbaek M, Peuckmann V, Sjogren P. Alcohol and smoking behavior in chronic pain patients: The role of opioids. Eur J Pain 2009;13(6):606-12.
39. John U, Baumeister SE, Volzke H, etal. Sedative, hypnotic, anxiolytic and opioid medicament use and its co-occurrence with tobacco smoking and alcohol risk drinking in a community sample. BMC Public Health 2007;7:337-49.
40. Darke S, Wodak A, Hall W, Heather N, Ward J. Prevalence and predictors of psychopathology among opioid users. Br J Addict 1992;87(5):771-6.
41. Regier DA, Farmer ME, Rae DS, etal. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264(19):2511-8.
42. Wasan AD, Butler SF, Budman SH, etal. Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. Clin J Pain 2007;23(4):307-15.
43. Passik SD, Kirsh KL. Opioid therapy in patients with a history of substance abuse. CNS Drugs 2004;18(1):13-25.
44. Passik SD, Kirsh KL. Assessing aberrant drug-taking behaviors in the patient with chronic pain. Curr Pain Headache Rep 2004;8(4):289-94.
45. Pergolizzi J, Pappagallo M, Stauffer J, etal. The role of urine drug testing for patients on opioid therapy. Pain Pract 2010;10(6):497-507.
46. Heit HA, Gourlay DL. Tackling the difficult problem of prescription opioid misuse. Ann Intern Med 2010;152(11):747-8.
47. Smith HK. Opioid Metabolism. Mayo Clin Proc 2009;84(7):613-24.
48. Moeller KE, Lee KC, Kissack JC. Urine drug screening: Practical guide for clinicians. Mayo Clin Proc 2008;83(1):66-76.
49. Katz N, Fanciullo GJ. Role of urine toxicology testing in the management of chronic opioid therapy. Clin J Pain 2002;18(4 suppl):S76-82.
50. Reisfield GM, Salazar E, Bertholf RL. Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann Clin Lab Sci 2007;37(4):301-14.
51. Jamison RN, Ross EL, Michna E, Chen LQ, Holcomb C, Wasan AD. Substance misuse treatment for high-risk chronic pain patients on opioid therapy: A randomized trial. Pain 2010;150(3):390-400.